# US 2003/0078409 A1 · Asthma associated factors as targets for treating atopic allergies including asthma and related disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0078409 A1
- Document ID: US20030078409A1
- Status: Published application
- Kind: A1
- Application number: 10/270,595
- Filed: 2002-10-16
- Published: 2003-04-24
- Earliest claimed: 1998-03-03
- Assignees: Magainin Pharmaceuticals Inc.
- Inventors: Kenneth J. Holroyd; Roy C. Levitt; W. Lee Maloy; Jamila Louahed; Mike McLane; Nicholas C. Nicolaides; Yuhong Zhou; Qu Dong
- Web page: https://patentgrep.com/patent/US20030078409A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- G01N 2500/00: Screening for compounds of potential therapeutic value
- Y10S 977/914: Protein engineering
- Y10S 977/927: Diagnostic contrast agent
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

A new gene in the calcium-activated chloride channel family has been discovered that is induced by IL-9, thereby providing a therapeutic target in IL-9 mediated development of atopic allergy, asthma-related disorders and cystic fibrosis. A method for the identification and use of small molecule inhibitors of this gene and its products to treat these disorders has also been discovered. The invention also includes a method for diagnosing susceptibility to, and assessing treatment of atopic allergy, asthma-related disorders by measuring the level of gene expression in biologic samples using antibody specific for this protein.

## Claims

### Claim 1

A purified and isolated nucleic acid molecule selected from the group consisting of a nucleic acid molecule having a nucleotide sequence encoding human ICACC-1 (SEQ ID NO:6), a nucleic acid molecule which hybridizes to a nucleic acid molecule having SEQ ID NO: 1 and a nucleic acid molecule comprising functionally effective fragments thereof.

### Claim 2

A purified and isolated DNA molecule having a nucleotide sequence encoding murine ICACC-1 (SEQ ID NO:2) or functionally effective fragments thereof.

### Claim 3

A purified and isolated DNA molecule having a nucleotide sequence encoding human ICACC-2 (SEQ ID NO:4) or functionally effective fragments thereof.

### Claim 4 (depends on 1, 2, 3)

The purified and isolated DNA molecule of claim 1, 2 or 3 wherein said DNA molecule is genomic.

### Claim 5

A chemically synthesized DNA molecule having a nucleotide sequence encoding human ICACC-1 or functionally effective fragments thereof.

### Claim 6

A chemically synthesized DNA molecule having a nucleotide sequence encoding murine ICACC-1 or functionally effective fragments thereof.

### Claim 7

A chemically synthesized DNA molecule having a nucleotide sequence encoding human ICACC-2 or functionally effective fragments thereof.

### Claim 8

A purified and isolated RNA molecule having a nucleotide sequence encoding human ICACC-1 or functionally effective fragments thereof.

### Claim 9

A purified and isolated RNA molecule having a nucleotide sequence encoding murine ICACC-1 or functionally effective fragments thereof.

### Claim 10

A purified and isolated RNA molecule having a nucleotide sequence encoding human ICACC-2 or functionally effective fragments thereof.

### Claim 11

A purified and isolated protein molecule having an amino acid sequence comprising human ICACC-1 (SEQ ID NO:6) or functionally effective fragments thereof.

### Claim 12

A purified and isolated protein molecule having an amino acid sequence comprising murine ICACC-1 (SEQ ID NO:2) or functionally effective fragments thereof.

### Claim 13

A purified and isolated protein molecule having an amino acid sequence comprising human ICACC-1 (SEQ ID NO:4) or functionally effective fragments thereof.

### Claim 14

A method of alleviating asthma by administering to patients in need of such treatment an effective amount of a compound to down-regulate the function of human ICACC-1.

### Claim 15 (depends on 14)

A method according to claim 14 wherein the compound is a chloride channel inhibitor.

### Claim 16 (depends on 14)

A method according to claim 14 wherein the compound is an aminosterol.

### Claim 17

A method of alleviating asthma by administering to patients in need of such treatment an effective amount of an antibody that blocks the function of an ICACC thereby down-regulating the activity of an ICACC-1.

### Claim 18 (depends on 17)

The method of claim 17 wherein the antibody is produced from peptides that encompass the functional domains of ICACC-1.

### Claim 19 (depends on 17)

A method according to claim 17 wherein the antibody is produced from peptides taken from the group of SEQ ID NO:11-15.

### Claim 20 (depends on 17)

The method of claim 17 wherein the antibody is monoclonal.

### Claim 21

A method for detecting or diagnosing susceptibility to asthma associated with elevated levels of an ICACC-1 polypeptide in a human subject comprising the steps of:
(a) measuring the level of the ICACC-1 polypeptide in a biological sample from said human subject; and
(b) comparing the level of ICACC-1 polypeptide present in normal subjects, wherein an increase in the level of ICACC-1 polypeptide as compared to normal levels indicates a predisposition to asthma.

### Claim 22

A method for monitoring a therapeutic treatment of asthma associated with elevated levels of an ICACC-1 polypeptide in a human subject comprising; measuring the levels of the ICACC-1 polypeptide in a series of biologic samples obtained at different time points from said subject undergoing therapeutic treatment wherein a significant decrease in said levels of ICACC-1 polypeptide indicates a successful therapeutic treatment.

### Claim 23 (depends on 11, 12)

A method of preparing an antibody specific to an ICACC polypeptide which comprises the protein molecule of claims 11 or 12 or fragments thereof comprising the steps of:
(a) conjugating an ICACC polypeptide which comprises SEQ ID NO:6 or SEQ ID NO:4 or fragments thereof containing at least ten amino acids to a carrier protein;
(b) immunizing a host animal with said ICACC polypeptide fragment-carrier protein conjugate admixed with an adjuvant; and
(c) obtaining antibody from the immunized host animal.

### Claim 24 (depends on 23)

A method according to claim 23 wherein the protein fragment is taken from the group of SEQ ID NO: 11-15.

### Claim 25 (depends on 11, 12)

A method of quantifying an ICACC polypeptide of claims 11 or 12 comprising the steps of:
(a) contacting a sample suspected of containing the ICACC polypeptide with an antibody that specifically binds to the ICACC polypeptide under conditions that allow for the formation of reaction complexes comprising the antibody and the ICACC polypeptides; and
(b) detecting the formation of reaction complexes comprising the antibody and the ICACC polypeptide in the sample, wherein quanatation of the reaction complexes indicates the level of the ICACC polypeptide in the sample.

### Claim 26

A method for identifying antagonists of an ICACC-1 comprising the steps of:
(a) obtaining non-human animals susceptible to airway hyperresponsiveness;
(b) administering antigens that induce airway hyperresponsiveness;
(c) comparing the characteristics of any resulting airway hyperresponsiveness with the characteristics of airway hyperresponsiveness obtained with pretreatment with a possible ICACC-1 antagonist agent; and
(d) selecting those agents for which pretreatment diminished the characteristics.

### Claim 27 (depends on 26)

The method of claim 26 wherein the animal expresses human ICACC-1.

### Claim 28

A method for identifying antagonists of an ICACC-1 comprising the steps of:
(a) obtaining a cell line that is responsive to IL-9;
(b) growing said cell line in the presence of IL-9;
(c) comparing the characteristics of IL-9 induction with those obtained with pretreatment with a possible ICACC-1 antagonist agent; and
(d) selecting those agents for which pretreatment diminished the characteristics.

### Claim 29 (depends on 27)

The method according to claim 27 wherein the cell line is: murine lung epithelial cells transfected with the human IL-9 receptor or human NHBE cells.

### Claim 30

Antisense DNA comprising the antisense sequence of a human ICACC-1 or active fragments thereof.

### Claim 31 (depends on 14, 30)

A method according to claim 14 wherein the compound is the antisense DNA of claim 30.

### Claim 32

A method of treating cystic fibrosis by administering to patients in need of such treatment an effective amount of a compound to up-regulate the function of a human ICACC.

### Claim 33

A method of treating inflammatory bowel disease by administering to patients in need of such treatment an effective amount of a compound to up-regulate the function of a human ICACC-1.

### Claim 34 (depends on 32, 33)

A method according to claims 32 or 33 wherein the compound is IL-9.

### Claim 35

A method for detecting or diagnosing susceptibility to inflammatory bowel disease associated with reduced levels of an ICACC-1 polypeptide in a human subject comprising the steps of:
(a) measuring the level of ICACC-1 polypeptide in a biological sample from said human subject; and
(b) comparing the level of ICACC-1 polypeptide present in normal subjects, wherein an decrease in the level of ICACC-1 polypeptide as compared to normal levels indicates a predisposition to inflammatory bowel disease.

### Claim 36

A method for monitoring a therapeutic treatment of inflammatory bowel disease associated with reduced levels of an ICACC-1 polypeptide in a human subject comprising; measuring the levels of ICACC-1 polypeptide in a series of biologic samples obtained at different time points from said subject undergoing therapeutic treatment wherein a significant increase in said levels of ICACC-1 polypeptide indicates a successful therapeutic treatment.
